Fast Five Quiz: Relapsed/Refractory Marginal Zone Lymphoma

Christina Poh, MD


November 03, 2021

The BTK inhibitors ibrutinib and zanubrutinib are FDA approved for the treatment of adults with relapsed/refractory MZL after at least one prior anti-CD20 monoclonal antibody–based regimen. The efficacy of ibrutinib and zanubrutinib was demonstrated in trials of MZL patients who relapsed after at least one anti-CD20 monoclonal antibody–containing regimen with overall response rates ranging from 58% to 80%.

Learn more about treatment of MZL.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.